lymphoma

[Clinical Cancer Research] Researchers performed targeted next-generation sequencing, immunohistochemistry for MYC, BCL2, and FN1, and fluorescent multiplex immunohistochemistry for microenvironmental markers in a large cohort of diffuse large B cell lymphoma.

[Molecular Cancer] CRISPR/Cas9 approaches were used to generate stem cell leukemia/lymphoma syndrome cells null for Interleukin receptor associated kinase 1 and interferon gamma which were introduced into syngeneic hosts through tail vein injection.

[New England Journal of Medicine] In a Phase III clinical trial, scientists randomly assigned, in a 1:1 ratio, patients with large B cell lymphoma that was refractory to or had relapsed no more than 12 months after first-line chemoimmunotherapy to receive axicabtagene ciloleucel or standard care.

[Laboratory Investigation] Investigators provided evidence that elevated levels of human SMO showed a strong correlation with elevated levels of insulin-like growth factor 1 receptor and reduced survival in diffuse large B-cell lymphoma.

[Nature Communications] The authors developed an anti-CD19 CAR comprised of the 4-1BB co-stimulatory and TNFRSF19 transmembrane domains, showing anti-tumor efficacy in an in vivo xenograft lymphoma model.

[Vincerx Pharma, Inc.] Vincerx Pharma, Inc. announced that the European Commission has granted Orphan Drug Designation to VIP152, the Company’s PTEFb/CDK9 inhibitor, for the treatment of diffuse large B cell lymphoma.